Download PDF
Fortschr Neurol Psychiatr 2020; 88(05): 337-348
DOI: 10.1055/a-1101-0904
Fort- und Weiterbildung

Demenz mit Lewy-Körpern

Dementia with Lewy bodies
Matthias W. Riepe
› Further Information
    Permissions and Reprints

Ein demenzielles Syndrom und eine parkinsonoide extrapyramidalmotorische Symptomatik sind häufig assoziiert. Allgemein etablierte Konsensuskriterien erlauben die Diagnose einer Lewy-Körper-Demenz – allerdings schließt diese auf klinischen Kriterien basierende Diagnose auch die Diagnose einer Demenz anderer Ätiologie nicht aus. Im klinischen Alltag treten häufig Mischformen mit begleitender Alzheimer-Erkrankung oder vaskulärer Enzephalopathie auf.

A dementia syndrome is often associated with parkinsonoid extrapyramidal motor symptoms. Established consensus criteria allow the diagnosis of Lewy body dementia - however, this diagnosis based on clinical criteria does not exclude the diagnosis of dementia of different etiology. In everyday clinical practice, mixed forms with concomitant Alzheimer’s disease or vascular encephalopathy do frequently occur.

Schlüsselwörter

Konsensuskriterien - kognitive Funktionen - Halluzinationen - Neuroleptika - vegetatives Nervensystem - Differenzialdiagnostik

Key words

Consensus criteria - cognitive functions - hallucinations - neuroleptics - autonomic nervous system - differential diagnosis


Publication History

Article published online:
18 May 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Capouch SD, Farlow MR, Brosch JR. A review of dementia with Lewy bodiesʼ impact, diagnostic criteria and treatment. Neurol Ther 2018; 7: 249-263
    CrossrefPubMedGoogle Scholar
  • 2 Luis CA, Barker WW, Gajaraj K. et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 1999; 14: 526-533
    CrossrefPubMedGoogle Scholar
  • 3 Tousi B. Diagnosis and management of cognitive and behavioral changes in dementia with Lewy bodies. Curr Treat Options Neurol 2017; 19: 42
    CrossrefPubMedGoogle Scholar
  • 4 McKeith IG, Boeve BF, Dickson DW. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89: 88-100
    CrossrefPubMedGoogle Scholar
  • 5 Clinton LK, Blurton-Jones M, Myczek K. et al. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-7289
    CrossrefPubMedGoogle Scholar
  • 6 Sarro L, Tosakulwong N, Schwarz CG. et al. An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimerʼs disease. Alzheimers Dement 2017; 13: 257-266
    CrossrefPubMedGoogle Scholar
  • 7 Gomperts SN, Locascio JJ, Marquie M. et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965-973
    CrossrefPubMedGoogle Scholar
  • 8 Beagle AJ, Darwish SM, Ranasinghe KG. et al. Relative incidence of seizures and myoclonus in Alzheimerʼs disease, dementia with Lewy bodies, and frontotemporal dementia. J. Alzheimers Dis 2017; 60: 211-223
    CrossrefPubMedGoogle Scholar
  • 9 Cagnin A, Gnoato F, Jelcic N. et al. Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2013; 84: 505-510
    CrossrefPubMedGoogle Scholar
  • 10 Rolma G, Jelcic N, Gnoato F. et al. Combined duloxetine and benzodiazepine-induced visual hallucinations in prodromal dementia with Lewy bodies. Gen Hosp Psychiatry 2013; 35: 678.e7-678.e9
    CrossrefPubMedGoogle Scholar
  • 11 Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125 (Pt 2): 391-403
    CrossrefPubMedGoogle Scholar
  • 12 Postuma RB, Iranzo A, Hu M. et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study. Brain 2019; 142: 744-759
    CrossrefPubMedGoogle Scholar
  • 13 Tzeng RC, Tsai CF, Wang CT. et al. Delusions in patients with dementia with Lewy bodies and the associated factors. Behav Neurol 2018; 2018: 6707291
    CrossrefPubMedGoogle Scholar
  • 14 Creese B, Ballard C, Aarsland D. et al. Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. Am J Geriatr Psychiatry 2014; 22: 580-586
    CrossrefPubMedGoogle Scholar
  • 15 Ziebell M, Andersen BB, Pinborg LH. et al. Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med 2013; 54: 1072-1076
    CrossrefPubMedGoogle Scholar
  • 16 Wennstrom M, Surova Y, Hall S. et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013; 8: e53250
    CrossrefPubMedGoogle Scholar
  • 17 Chiu PY, Hsu MH, Wang CW. et al. Visual hallucinations in Alzheimerʼs disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies. PLoS One 2017; 12: e0186886.
    CrossrefPubMedGoogle Scholar
  • 18 Sugawara Kikuchi Y, Shimizu T. Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: A case series. Neuropsychiatr Dis Treat 2019; 15: 543-547
    CrossrefPubMedGoogle Scholar
  • 19 Friedman JH. Pimavanserin for psychotic symptoms in people with parkinsonism: A second chart review. Clin Neuropharmacol 2018; 41: 156-159
    CrossrefPubMedGoogle Scholar
  • 20 Meng YH, Wang PP, Song YX. et al. Cholinesterase inhibitors and memantine for Parkinsonʼs disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med 2019; 17: 1611-1624
    PubMedGoogle Scholar